A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 Oral Solution in the Treatment of Subjects With Essential Tremor

Trial Profile

A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 Oral Solution in the Treatment of Subjects With Essential Tremor

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Essential tremor
  • Focus Therapeutic Use
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 04 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Nov 2017 According to a Sage Therapeutics media release, Top-line results from Part C are expected in 4Q 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top